Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Subtypes in BRCA-mutated breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early metastatic colorectal cancers show increased tissue expression of miR-17/92 cluster members in the invasive tumor front

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of nonaspirin nonsteroidal anti-inflammatory drugs and risk of head and neck cancer: A nationwide case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prevalence, type distribution, and risk factors for oral HPV in Danish renal transplant recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Human papillomavirus vaccination in immigrants and descendants of immigrants in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Deyin Xing
  • Yohan Suryo Rahmanto
  • Felix Zeppernick
  • Charlotte G Hannibal
  • Susanne K Kjaer
  • Russell Vang
  • Ie-Ming Shih
  • Tian-Li Wang
Vis graf over relationer

Activating mutations involving the members of the RAS signaling pathway, including KRAS, NRAS, and BRAF, have been reported in ovarian low-grade serous carcinoma and its precursor lesion, serous borderline tumor (SBT). Whether additional genetic alterations in the RAS oncogene family accumulate during the progression of SBT to invasive low-grade serous carcinoma (LGSC) remains largely unknown. Although mutations of KRAS and BRAF occur at a very early stage of progression, even preceding the development of SBT, additional driving events, such as NRAS mutations, have been postulated to facilitate progression. In this study, we analyzed NRAS exon 3 mutational status in 98 cases that were diagnosed with SBT/atypical proliferative serous tumor, noninvasive LGSC, or invasive LGSC. Of the latter, NRAS Q61R (CAA to CGA) mutations were detected in only 2 of 56 (3.6%) cases. The same mutation was not detected in any of the SBTs (atypical proliferative serous tumors) or noninvasive LGSCs. Mutational analysis for hotspots in KRAS and BRAF demonstrated a wild-type pattern of KRAS and BRAF in one of the NRAS-mutated cases. Interestingly, another LGSC case with NRAS mutation harbored a concurrent BRAF V600L mutation. These findings indicate that, although recurrent NRAS mutations are present, their low prevalence indicates that NRAS plays a limited role in the development of LGSC. Further studies to identify other oncogenic events that drive LGSC progression are warranted.

OriginalsprogEngelsk
TidsskriftHuman Pathology
Vol/bind68
Sider (fra-til)87-91
ISSN0046-8177
DOI
StatusUdgivet - okt. 2017

ID: 52206343